** Shares of therapy developer Neurogene fall 46.9% to $37.99 aftermarket
** Co says it does not expect to move forward with the development of its gene therapy for Batten disease
** Says the decision was made after the FDA denied co's Regenerative Medicine Advance Therapy (RMAT) application to the FDA for the gene therapy
** A therapy is eligible for RMAT designation if it is used for treating a serious or life-threatening disease or condition and if preliminary clinical evidence shows the therapy has potential to address unmet medical needs
** Co says it is currently evaluating options for the developmental program
** Batten disease is a rare, inherited, and fatal disorder that affects the nervous system
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。